Auro Laboratories Share Price & Earnings Call Analysis
- Market cap
- ₹143 Cr
- P/E
- 29.80
- ROE
- 8.49%
- PEG
- 1.89
- Price to sales
- 3.87
- Debt to equity
- 1.37
- 52W high / low
- ₹302 / ₹179
- Sales growth (5Y)
- -10.74%
- EBITDA margin
- 35.41%
- Net profit margin
- 12.33%
- Promoter holding
- 52.40%
- Sales (last year)
- ₹37 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Auro Laboratories.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Auro Laboratories
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Auro Laboratories
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2024 | Jun 2025 | Sep 2025 | |
|---|---|---|---|
| Sales + | 3.10 | 2.77 | 8.84 |
| Expenses + | 2.38 | 2.74 | 6.49 |
| Operating Profit | 0.72 | 0.03 | 2.35 |
| OPM % | 23.23% | 1.08% | 26.58% |
| Other Income + | 0.31 | 0.42 | 0.98 |
| Interest | 0.28 | 0.28 | 0.96 |
| Depreciation | 0.27 | 0.27 | 0.65 |
| Profit before tax | 0.48 | -0.10 | 1.72 |
| Tax % | 25.00% | 0.00% | 58.14% |
| Net Profit + | 0.36 | -0.11 | 0.72 |
| EPS in Rs | 0.58 | -0.18 | 1.16 |
Financials of Auro Laboratories
Profit & Loss
Annual income statement trend
| Mar 2025 | |
|---|---|
| Sales + | 19.40 |
| Expenses + | 16.00 |
| Operating Profit | 3.40 |
| OPM % | 17.53% |
| Other Income + | 0.66 |
| Interest | 1.08 |
| Depreciation | 1.10 |
| Profit before tax | 1.88 |
| Tax % | 2.13% |
| Net Profit + | 1.84 |
| EPS in Rs | 2.95 |
| Dividend Payout % | 0.00% |
Financials of Auro Laboratories
Balance Sheet
Capital structure and asset base
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 6.23 | 6.23 |
| Reserves | 36.74 | 37.35 |
| Borrowings + | 42.72 | 43.94 |
| Other Liabilities + | 13.41 | 23.25 |
| Total Liabilities | 99.10 | 110.77 |
| Fixed Assets + | 21.05 | 76.84 |
| CWIP | 56.48 | 10.37 |
| Investments | 0.05 | 0.05 |
| Other Assets + | 21.52 | 23.51 |
| Total Assets | 99.10 | 110.77 |
Financials of Auro Laboratories
Cash Flows
Operating, investing and financing cash movement
| Mar 2025 | |
|---|---|
| Cash from Operating Activity + | |
| Cash from Investing Activity + | |
| Cash from Financing Activity + | |
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Financials of Auro Laboratories
Ratios
Working capital efficiency and return ratios
| Mar 2025 | |
|---|---|
| Debtor Days | 176.67 |
| Inventory Days | 145.45 |
| Days Payable | 246.11 |
| Cash Conversion Cycle | 76.01 |
| Working Capital Days | -14.30 |
| ROCE % |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.